Long-term HIV-specific responses and delayed resumption of antiretroviral therapy after peptide immunization targeting dendritic cells.
Long-term HIV-specific immune responses and clinical outcomes were evaluated in HIV-infected patients previously immunized with p24-like peptides (Vacc-4x) targeting dendritic cells (DC). Vacc-4x-induced cellular immune responses were unchanged 1.5 years after completing immunization, and 62% were still off combined antiretroviral treatment (CART). The magnitude of early Vacc-4x responses determined whether the resumption of CART was clinically indicated 2 years after enrollment. These observations encourage further exploration of both Vacc-4x and other HIV peptide-based immunization regimens targeting DC.
Ullevål University Hospital, University of Oslo, Department of Infectious Diseases, NO-0407 Oslo, Norway.
Anne-Marte B
AM
Kran
Birger
B
Sørensen
Maja A
MA
Sommerfelt
Jørgen
J
Nyhus
Ingebjørg
I
Baksaas
Dag
D
Kvale
D016915:AIDS Vaccines / Q000276:immunology*; D023241:Antiretroviral Therapy, Highly Active; D003713:Dendritic Cells / Q000276:immunology*; D015658:HIV Infections / Q000188:drug therapy / Q000276:immunology* / Q000517:prevention & control; D006801:Humans; D007111:Immunity, Cellular / Q000502:physiology; D007114:Immunization / Q000379:methods; D014766:Viremia / Q000276:immunology
D016915:AIDS Vaccines; C494182:Vacc-4x